Real World Evidence (RWE)
RWE describes evidence relating to patient health or experience or care delivery collected in the ‘real world’, i.e. outside of controlled research studies. The quality of RWE varies widely and its use is not consistently accepted but it has the potential to reduce uncertainty and improve decision-making.
New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options
1 April 2011
Antimicrobial resistance (AMR) to drugs is a natural and unavoidable consequence of treating infectious diseases. A growing global public health threat, AMR reduces the chances of…
Exploring the Interdependency between Public and Charitable Medical Research
1 April 2011
Continuing concern about the fiscal deficit makes it likely that government funding of health and medical research will remain under scrutiny. This OHE Consulting study, commissioned…
Incentives for R&D for New Antimicrobial Drugs
1 April 2011
Antimicrobial resistance (AMR) is becoming a major global public health threat and has begun to command attention from European and US policy makers. An initial focus…
Priority Review Vouchers to Encourage Innovation for Neglected Diseases
1 January 2011
Priority Review Vouchers (PRVs) are awarded in the US to companies that gain approval there for a new drug for one of sixteen tropical diseases, under…
New Drugs to Tackle Antimicrobial Resistance: EU Policy Options
1 October 2010
Antimicrobial resistance (AMR) to drugs, a natural and unavoidable consequence of treating infectious diseases, is a growing global public health threat. The EU Commission is to…
Enhancing the Benefits from Biomedical and Health Research Spillovers
1 October 2010
Research spillovers may exist when research by one organisation creates increased output for other organisations that operate in the same or another sector of the economy. …
Innovation in Medicines: Can We Value Progress?
1 August 2010
Summarised in this publication are the main points and conclusions from a discussion facilitated by OHE that focused on innovation in the pharmaceutical industry. Participants included…
Forward Together: Complementarity of Public and Charitable Research with Respect to Private Research Spending
9 January 2009
The debate continues as to whether public/charitable research replaces private research that otherwise would have occurred, or stimulates additional private research, or does neither. Given the…
Medical Research: What’s It Worth?
1 November 2008
Understanding the nature, extent and processes involved in the return on investment in medical research has been largely neglected as an area of serious scientific study.…